News Search Results
Jun 11, 2025, 10:09 ET Alamar Biosciences, Alzheimer's Disease Data Initiative, dan Gates Ventures Bersatu dalam Kemitraan Global untuk Memajukan Penelitian Translasi Tentang Penyakit Alzheimer.
NULISAseq™ CNS Disease Panel 120 dan
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 10:06 ET Alamar Biosciences、Alzheimer's Disease Data Initiative、Gates Venturesが連携し、アルツハイマー病のトランスレーショナルリサーチを推進する国際的パートナーシップを締結
NULISAseq™ CNS Disease Panel 120および
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 10:02 ET Alamar Biosciences, Alzheimer's Disease Data Initiative i Gates Ventures jednoczą się w ramach międzynarodowej współpracy na rzecz rozwoju badań translacyjnych nad chorobą Alzheimera
NULISAseq™ CNS Disease Panel 120 oraz
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 09:30 ET "STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 16-19 JUNE, 2025
/PRNewswire/ -- The represented biotech companies primarily focus on therapeutics development across oncology, respiratory diseases, rare diseases, and CNS disorders, alongside advanced drug discovery technologies including 3D microtissues, transcriptomics, and novel delivery systems.
More news about: Swiss Business Hub USA
Jun 11, 2025, 08:00 ET Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
Jun 11, 2025, 03:32 ET 알라마르 바이오사이언시즈 •알츠하이머병 데이터 이니셔티브•게이츠 벤처스, 알츠하이머병의 중개연구 진전시키기 위한 글로벌 파트너십 체결
NULISAseq™ CNS 질환 패널 120(NULISAseq™ CNS Disease Panel 120) 및
More news about: Alamar Biosciences, Inc.
Jun 11, 2025, 01:38 ET Alamar Biosciences、Alzheimer's Disease Data Initiative 與 Gates Ventures 建立全球合作夥伴關係，推進阿茲海默症的轉化研究。
NULISAseq™ CNS 疾病專家小組 120 和
More news about: Alamar Biosciences, Inc.
Jun 10, 2025, 14:22 ET Alamar Biosciences, la Iniciativa de Datos sobre la Enfermedad de Alzheimer y Gates Ventures se unen en la EA
NULISAseq™ CNS Disease Panel 120 e
More news about: Alamar Biosciences, Inc.
Jun 10, 2025, 09:12 ET Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
NULISAseq™ CNS Disease Panel 120 and
More news about: Alamar Biosciences, Inc.
Jun 10, 2025, 09:12 ET Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
NULISAseq™ CNS Disease Panel 120 and
More news about: Alamar Biosciences, Inc.
Jun 10, 2025, 05:00 ET World Precision Instruments and SynVivo Announce Launch of EVOM™ Chip-A Breakthrough Multiplex TEER System Enabling Real-Time Organ-on-Chip Monitoring
technology with WPI's industry-leading TEER measurement expertise, we're delivering a powerful solution for researchers tackling complex questions in CNS, inflammation, and drug discovery." The EVOM™ Chip system will standardize TEER measurements across SynVivo's OOC platforms,
More news about: World Precision Instruments, Inc.
Jun 09, 2025, 18:00 ET Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse and misuse,
More news about: Jazz Pharmaceuticals plc
Jun 09, 2025, 16:23 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025
YORK, June 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of May 31, 2025,
More news about: Cohen & Steers, Inc.
Jun 09, 2025, 12:45 ET Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships
pipeline and global footprint through five major transactions in under a year. Minji brings deep experience in oncology, immunology, ophthalmology, CNS, cardiovascular, and digital therapeutics, and has led both in- and out-licensing from early discovery to late-stage clinical assets. She is the Founder
More news about: Formation Bio
Jun 05, 2025, 17:31 ET Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight
Leriglitazone, a product of Minoryx Therapeutics, is an orally active, selective PPARγ agonist with a promising profile for central nervous system (CNS) disorders. It was designated an Orphan Drug by both the FDA and EMA in 2019 for Friedreich's ataxia. Clinical evaluation in Phase II trials showed
More news about: DelveInsight Business Research, LLP
Jun 05, 2025, 13:00 ET BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration
innovations included non-viral CRISPR-Cas12Max therapies for retinal disorders (90% primate model efficacy) and Duchenne MD gene therapies, while metabolic/CNS advances featured dual GLP-1/GIP agonists outperforming competitors in weight loss trials and tau-targeting Alzheimer's mAbs. With 50% of
More news about: bioSeedin
Jun 05, 2025, 08:00 ET Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation
More news about: Kazia Therapeutics Limited
Jun 03, 2025, 14:16 ET Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
FluidCrystal technology in rapidly expanding indication areas impacting hundreds of millions of people, while maintaining our own commercial focus on CNS and rare diseases." In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic
More news about: Camurus AB
Jun 03, 2025, 14:12 ET Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
FluidCrystal technology in rapidly expanding indication areas impacting hundreds of millions of people, while maintaining our own commercial focus on CNS and rare diseases." In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic
More news about: Camurus AB
Jun 03, 2025, 08:00 ET GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
Simon Hanft, MD, Neurosurgeon, Section Chief, Neurosurgical OncologyRohil Shekher, MD, Radiation Oncologist, CNS Program Lead"Receiving recognition as a GammaTile Center of Excellence is a meaningful acknowledgment of our team's dedication
More news about: GT Medical Technologies
Jun 02, 2025, 21:00 ET XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
allogeneic iPSC-derived cell therapies targeting central nervous system (CNS) diseases with no effective treatment options. XellSmart is at the forefront of advancing innovative iPSC-based therapies to address major and intractable CNS disorders:In 2023, China's
More news about: XellSmart
Jun 02, 2025, 17:31 ET Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by Novel Therapeutic Advancements | DelveInsight
inhibiting the expression of UBE3A-AS. Preclinical studies suggest that GTX-102 reduces UBE3A-AS levels and reactivates the paternal UBE3A allele in CNS neurons. GTX-102 has received Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the FDA, as well as
More news about: DelveInsight Business Research, LLP
Jun 02, 2025, 07:00 ET Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
dosage of LYBALVI when using with strong CYP1A2 inhibitors. Increase dosage of LYBALVI with CYP1A2 inducers. Use caution with diazepam, alcohol, other CNS acting drugs, or in patients receiving anticholinergic (antimuscarinic) medications. Monitor blood pressure and reduce dosage of antihypertensive drug
More news about: Alkermes plc
May 30, 2025, 19:36 ET HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options
whose tumors contained an EGFR or KRAS mutation. Overall, the data suggest that HER3-DXd may offer a novel treatment option for patients with secondary CNS involvement. KEY HIGHLIGHTS OF THE TUXEDO-3 STUDY The TUXEDO-3 study aimed to assess whether HER3-DXd could be an effective treatment
More news about: MEDSIR
May 30, 2025, 07:00 ET Lightedge Scales Global DDoS Protection with $1.2M Corero Network Security Expansion
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) announced a $1.2 million expansion of its partnership with
More news about: Corero Network Security